Simplex Trading
ZNTL icon

Simplex Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Simplex Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.7K Sell
2,000
-100
-5% -$399 ﹤0.01% 7717
2026
Q1 		$4.91K Buy
+2,100
New +$5.42K ﹤0.01% 7910
2025
Q4 		– Sell
-43,000
Closed -$64K – 10324
2025
Q3 		$64K Buy
+43,000
New +$64.5K ﹤0.01% 6211
2025
Q2 		– Sell
-2,900
Closed -$4K – 9909
2025
Q1 		$4K Sell
2,900
-29,400
-91% -$63.4K ﹤0.01% 7751
2024
Q4 		$97K Sell
32,300
-14,500
-31% -$47.5K ﹤0.01% 5201
2024
Q3 		$172K Buy
46,800
+44,700
+2,129% +$162K ﹤0.01% 4674
2024
Q2 		$8K Sell
2,100
-300
-13% -$3.35K ﹤0.01% 7628
2024
Q1 		$37K Sell
2,400
-54,100
-96% -$744K ﹤0.01% 6568
2023
Q4 		$855K Buy
56,500
+44,500
+371% +$649K ﹤0.01% 3150
2023
Q3 		$240K Buy
12,000
+5,800
+94% +$147K ﹤0.01% 4167
2023
Q2 		$174K Buy
6,200
+1,500
+32% +$36K ﹤0.01% 4459
2023
Q1 		$80K Sell
4,700
-3,600
-43% -$72.9K ﹤0.01% 5415
2022
Q4 		$167K Sell
8,300
-900
-10% -$19.4K ﹤0.01% 4457
2022
Q3 		$199K Buy
9,200
+5,100
+124% +$139K ﹤0.01% 4617
2022
Q2 		$115K Sell
4,100
-27,700
-87% -$734K ﹤0.01% 5385
2022
Q1 		$1.47M Buy
31,800
+24,600
+342% +$1.33M ﹤0.01% 2434
2021
Q4 		$605K Buy
7,200
+7,000
+3,500% +$542K ﹤0.01% 3547
2021
Q3 		$10K Hold
200
– – ﹤0.01% 8948
2021
Q2 		$10K Buy
+200
New +$10.7K ﹤0.01% 9119

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Simplex Trading's ZNTL Position: Q2 2026 in Review

Simplex Trading reduced its Zentalis Pharmaceuticals (ZNTL) stake by 20% in Q2 2026, selling an estimated $78.4K and leaving 78,904 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #3947.

Simplex Trading first reported a position in ZNTL in Q3 2023 and has held it in 8 quarters since. The position peaked at $470K in Q4 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Simplex Trading held 78,904 shares of Zentalis Pharmaceuticals worth $383K as of Q2 2026.
  • Simplex Trading sold 19,650 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $78.4K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3947 holding.
  • Simplex Trading first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • Simplex Trading's Zentalis Pharmaceuticals position peaked at $470K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.